These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7926967)

  • 21. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.
    Souza PS; Vasconcelos FC; De Souza Reis FR; Nestal De Moraes G; Maia RC
    Int J Oncol; 2011 Oct; 39(4):925-33. PubMed ID: 21720708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
    Kantarjian H; O'Brien S; Cortes J; Giles F; Thomas D; Kornblau S; Shan J; Beth Rios M; Keating M; Freireich E; Talpaz M
    Cancer; 2003 Jul; 98(1):81-5. PubMed ID: 12833459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases.
    Damiani D; Michieli M; Michelutti A; Pea F; Baraldo M; Fanin R; Russo D; Furlanut M; Baccarani M
    Leukemia; 1995 Oct; 9(10):1792-5. PubMed ID: 7564529
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein.
    Seymour JF; Grill V; Martin TJ; Lee N; Firkin F
    Leukemia; 1993 Oct; 7(10):1672-5. PubMed ID: 8412332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of FHIT expression in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
    Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
    Pahore ZA; Shamsi TS; Taj M; Farzana T; Ansari SH; Nadeem M; Ahmad M; Naz A
    J Coll Physicians Surg Pak; 2011 Aug; 21(8):472-5. PubMed ID: 21798133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
    Michieli M; Damiani D; Geromin A; Michelutti A; Fanin R; Raspadori D; Russo D; Visani G; Dinota A; Pileri S
    Eur J Haematol; 1992 Feb; 48(2):87-92. PubMed ID: 1347749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
    Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.
    Raanani P; Trakhtenbrot L; Rechavi G; Rosenthal E; Avigdor A; Brok-Simoni F; Leiba M; Amariglio N; Nagler A; Ben-Bassat I
    Acta Haematol; 2005; 113(3):181-9. PubMed ID: 15870488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence in situ hybridization (FISH) detection of trisomy 8 in myeloid cells in chronic myeloid leukemia (CML): a study of archival blood and bone marrow smears.
    Nguyen PL; Arthur DC; Litz CE; Brunning RD
    Leukemia; 1994 Oct; 8(10):1654-62. PubMed ID: 7934161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Functional activity and expression of P-glycoprotein in chronic myeloid leukemia].
    Stromskaia TP; Rybalkina EIu; Turkina AG; Zabotina TN; Logacheva NP; Zakharova ES; Mechetner EB; Baryshnikov AIu; Khoroshko ND; Stavrovskaia AA
    Ter Arkh; 2001; 73(7):20-5. PubMed ID: 11523404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The correlation between p170, p26 and multidrug resistance in refractory/relapse acute leukemia].
    Gao X; Zhang X; Qiao Z
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):67-9. PubMed ID: 10921104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.